Roche’s Tecentriq combo extends life in untreated lung cancer
pharmafile | June 25, 2018 | News story | Research and Development, Sales and Marketing | Cancer, Roche, lung cancer, pharma, tecentriq
Roche has unveiled new data on the efficacy of Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the treatment of previously untreated extensive-stage small cell lung cancer (ES-SCLC), revealing that the combo met its co-primary endpoints and was proven to significantly extend life for compared to chemotherapy alone.
The study marked the fourth positive Phase 3 lung cancer study for Tecentriq this year, and the fifth positive study overall. The findings of the study also showed that the combination, when used as a first-line treatment, improved progression-free survival (PFS) versus chemotherapy alone, while its safety profile proved to be consistent with the known profiles of the individual medicines involved. Roche said the new data would be presented at an upcoming medical meeting.
“These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer, a particularly difficult-to-treat type of disease,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “The clinically meaningful results from the IMpower133 study add to the growing body of evidence demonstrating that Tecentriq-based combinations may be an effective treatment for different types of advanced lung cancer. We look forward to working with health authorities globally to bring this potential treatment option to people with this type of disease as soon as possible.”
Matt Fellows
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …
